A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
Public ClinicalTrials.gov record NCT01340053. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of RDX5791 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for the Diagnosis of IBS will undergo a battery of screening procedures to determine eligibility for the trial. The study will consist of a 2-week treatment-free screening period, a 4-week blinded treatment period, and a 2-week treatment-free follow-up period.
Study identification
- NCT ID
- NCT01340053
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 186 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2011
- Primary completion
- Nov 30, 2011
- Completion
- Jan 31, 2012
- Last update posted
- Oct 14, 2019
2011 – 2012
United States locations
- U.S. sites
- 16
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ardelyx Investigational Site | San Diego | California | 92108 | — |
| Ardelyx Investigational Site | Jupiter | Florida | 33458 | — |
| Ardelyx Investigational Site | Pinellas Park | Florida | 33782 | — |
| Ardelyx Investigational Site | Rockford | Illinois | 61107 | — |
| Ardelyx Investigational Site | Mission | Kansas | 66202 | — |
| Ardelyx Investigational Site | Monroe | Louisiana | 71201 | — |
| Ardelyx Investigational Site | Annapolis | Maryland | 21401 | — |
| Ardelyx Investigational Site | Chesterfield | Michigan | 48047 | — |
| Ardelyx Investigational Site | St Louis | Missouri | 63128 | — |
| Ardelyx Investigational Site | Brooklyn | New York | 11214 | — |
| Ardelyx Investigational Site | Greensboro | North Carolina | 27408 | — |
| Ardelyx Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Ardelyx Investigational Site | Simpsonville | South Carolina | 29681 | — |
| Ardelyx Investigational Site | Bristol | Tennessee | 37620 | — |
| Ardelyx Investigational Site | Ogden | Utah | 84405 | — |
| Ardelyx Investigational Site | Lynchburg | Virginia | 24502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01340053, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2019 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01340053 live on ClinicalTrials.gov.